Clinical trials: Residual
Major Depressive Disorder
Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability
Iloperidone is an atypical antipsychotic drug, FDA-approved for the acute treatment of schizophrenia in adults in 2009 (Marino et al., 2010); moreover, some of its pharmacological features seem to be very promising in treating…
- Trial name
- NCT01464229
- Testing
- Iloperidone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maurizio Fava, MD
Acute Lymphoblastic Leukemia
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.
- Trial name
- NCT00560794
- Testing
- Blinatumomab (MT103)
- Where
- 6 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Amgen Research (Munich) GmbH
Schizophrenia
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple…
- Trial name
- NCT01244828
- Testing
- Asenapine
- Volunteers
- 157 people
- Sponsor
- Organon and Co
Triple Negative Breast Cancer
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
This pilot study will provide preliminary data regarding the role of PIS in predicting the benefit of immune checkpoint inhibition with or without chemotherapy for high risk patients with TNBC and residual disease after effective…
- Trial name
- NCT03487666
- Testing
- Nivolumab, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Georgetown University
B-cell Acute Lymphoblastic Leukemia
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
- Trial name
- BLAST (NCT01207388)
- Testing
- Blinatumomab
- Where
- 75 sites in Austria, Belgium and 9 more
- Volunteers
- 116 people
- Sponsor
- Amgen Research (Munich) GmbH
Relapsed/Refractory AML, Minimal Residual Disease Positive AML
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
The purpose of this First-in-Human Phase 1 study is to determine if AMG 330 given as a continuous IV infusion is safe and tolerable in adult subjects that have myeloid malignancies, and to determine the maximum tolerated dose…
- Conditions
- Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome
- Trial name
- NCT02520427
- Testing
- AMG 330
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Amgen
Opioid-use Disorder, HIV-1-infection
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut.
- Conditions
- Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation
- Trial name
- AMOHI-1 (NCT04480554)
- Testing
- Methadone, Buprenorphine/naloxone, XR-Naltrexone
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
Grade 2 Glioma, Residual Glioma
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2…
- Conditions
- Grade 2 Glioma, Residual Glioma, Recurrent Glioma
- Trial name
- NCT04164901
- Testing
- Vorasidenib
- Where
- 84 sites in United States, Canada and 9 more
- Volunteers
- 331 people
- Sponsor
- Institut de Recherches Internationales Servier
Parkinson Disease, Tremor
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual…
- Trial name
- NCT05642442
- Testing
- Suvecaltamide
- Where
- 37 sites in United States, Germany and 2 more
- Volunteers
- 169 people
- Sponsor
- Jazz Pharmaceuticals
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
This phase II trial studies how well an umbilical cord blood transplant with added sugar works with chemotherapy and radiation therapy in treating patients with leukemia or lymphoma.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03096782
- Testing
- Anti-Thymocyte Globulin, Busulfan, Clofarabine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Hormonreceptor Positive
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
The PENELOPEB study is designed to demonstrate that, in the background of standard anti-hormonal therapy, palbociclib provides superior invasive disease-free survival (iDFS) compared to placebo in pre- and postmenopausal women…
- Conditions
- Breast Cancer, Hormonreceptor Positive, Her2-normal, Postneoadjuvant Treatment With CDK 4/6 Inhibitor
- Trial name
- PENELOPE-B (NCT01864746)
- Testing
- Palbociclib PD-0332991
- Where
- 11 sites in United States, Australia and 9 more
- Volunteers
- 1,250 people
- Sponsor
- GBG Forschungs GmbH
Cystic Fibrosis
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual…
- Trial name
- NCT05076149
- Testing
- VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA
- Where
- 170 sites in United States, Australia and 18 more
- Volunteers
- 597 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Phantom Limb Pain, Residual Limb Pain
Pulsed Electromagnetic Fields for Post-Amputation Pain
Pulsed electromagnetic field therapy is a possible method of pain control involving the application of electromagnetic energy (also termed nonthermal, pulsed, shortwave radiofrequency therapy).
- Trial name
- NCT05392803
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Diego
Neuromuscular Blockade, Postoperative Complications
Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery
The investigators will conduct a prospective, randomized trial to assess the impact of neuromuscular blockade on early (<72 hours post-ICU admission) postoperative respiratory complications in cardiac surgical patients.
- Trial name
- NCT02635542
- Testing
- Succinylcholine, Cisatracurium
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Chicago
Breast Cancer
Intraoperative Detection of Residual Cancer in Breast Cancer
This is a non-randomized, open-label, multi-site study to collect safety and efficacy data on an intraoperative imaging system, the LUM Imaging System (LUM015 imaging agent in conjunction with the LUM imaging device), in…
- Trial name
- NCT03321929
- Testing
- LUM Imaging System
- Where
- 16 sites in United States
- Volunteers
- 234 people
- Sponsor
- Lumicell, Inc.
Lower Extremity Amputation
Adherence and Perspiration While Wearing Lower Limb Prostheses
Individuals with lower limb amputation often complain about uncomfortable residual limb skin temperatures and the accumulation of sweat inside their prostheses.
- Trial name
- NCT03900845
- Testing
- Dynamic Air Exchange - Rising Edge Design (DAE-RED), Perforated elastomeric liner, As-prescribed prosthesis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
HIV Infection
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Background: Antiretroviral therapy (ART) has been able to improve the lifespan of individuals infected with human immunodeficiency virus type 1 (HIV-1), but ART requires continuous treatment that has substantial consequences on…
- Trial name
- NCT01295515
- Testing
- Pegylated Interferon Alpha 2b (PEGINTRON)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Infant, Premature, Nutrition, Enteral
Aspiration of Residual Gastric Contents
The primary purpose of this study is to determine nutrition outcomes and risks to gastrointestinal integrity and function of aspirating for routine gastric contents prior to each feeding in very low birth weight premature infants.
- Trial name
- NCT01863043
- Testing
- No aspiration of gastric contents, Routine aspiration of gastric contents
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- University of Florida
Thyroid Cancer
Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
The purpose of this study is to determine [for patients with previously treated well-differentiated thyroid cancer and evidence of residual disease based on serum thyroglobulin (Tg) level] whether positron emission…
- Trial name
- NCT00181168
- Testing
- Euthyroid Group
- Where
- 3 sites in United States, France
- Volunteers
- 63 people
- Sponsor
- Johns Hopkins University
Leukemia, Lymphoma
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
The goal of this clinical research study is to find out if ofatumumab can control CLL or SLL that is left after chemotherapy or chemoimmunotherapy. The safety of the drug will also be studied.
- Trial name
- NCT01258933
- Testing
- Ofatumumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center